Novavax, Inc. (NASDAQ:NVAX) reported its EPS in the last quarter as $-0.15/Share beating the analyst estimate of $-0.16/Share by a difference of $0.01. Out of the analyst recommendations 2 rate Novavax Inc (NASDAQ:NVAX) stock a Buy, 0 rate the stock Outperform, 5 rate Hold, 0 rate Underperform and 0 recommend a Sell.
NVAX has been the topic of several research reports. BidaskClub lowered Novavax from a "hold" rating to a "sell" rating in a research report on Wednesday, July 19th. Shares of NVAX moved upward with change of 2.88% to its 50-day Moving average.
Novavax Inc (NASDAQ:NVAX) as of recent trade, has shown weekly upbeat performance of 8.85% which was maintained at 20.59% in 1-month period. Shares opened today at $1.22. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company's stock.
Shares of Novavax (NVAX) traded up $0.06 during midday trading on Thursday, reaching $1.29. Trading volume for Novavax, Inc. was 5.03 Million in its previous trading session. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31. For the current quarter Novavax Inc (NASDAQ:NVAX) has high EPS estimates of $-0.14 in contradiction of low EPS estimates of $-0.18.
Novavax (NASDAQ:NVAX) last announced its earnings results on Tuesday, November 7th. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. However, 7.41% over the last one month, 17.22% for the last quarter and year to date performance stands at -7.94%. A stock with a beta more than 1 means high volatile and less than 1 means low volatile.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another website, it was illegally stolen and republished in violation of USA & worldwide copyright & trademark laws.
In other Novavax news, insider Stanley C. Erck purchased 100,000 shares of the firm's stock in a transaction that occurred on Thursday, November 9th. Novavax's revenue was up 158.5% compared to the same quarter last year. analysts expect that Novavax will post -0.63 earnings per share for the current fiscal year. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Currently, 13.8% of the shares of the company are short sold. Its beta value stands at 1.93. The disclosure for this sale can be found here. Hot Stocks Point (HSP) makes sure to keep the information up to date and correct, but we didn't suggest or recommend buying or selling of any financial instrument unless that information is subsequently confirmed on your own. HighTower Advisors LLC lifted its position in shares of Novavax by 3.8% during the 1st quarter. However, the institutional investors are observed to own 40.60% of the total shares. Raymond James Financial Services Advisors Inc. boosted its stake in Novavax by 49.8% in the 2nd quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company's stock valued at $184,000 after acquiring an additional 5,250 shares during the period. Bank of New York Mellon Corp lifted its position in Novavax by 0.9% during the first quarter. Wells Fargo & Company MN lifted its position in Novavax by 2.7% during the first quarter. Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company's stock valued at $185,000 after acquiring an additional 69,600 shares during the period. Finally, Amalgamated Bank raised its position in shares of Novavax by 1.1% in the second quarter. The stock hit its twelve month high on 02/16/17, and twelve month low on 05/08/17.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.